Here is the first part of a story which ran Wednesday in The Myeloma Beacon:
Higher Quality Response To Revlimid-Dexamethasone Combination Yields Better Prognosis For Relapsed And Refractory Multiple Myeloma Patients
By Michelle Spektor – Published July 28, 2010
A statistical analysis of two Phase 3 trials found relapsed and refractory multiple myeloma patients who achieved complete remission and very good partial response to Revlimid and dexamethasone combination treatment had higher overall survival rates and longer times to disease progression compared to patients who only achieved partial response.
The analysis also showed that patients’ response to Revlimid and dexamethasone improved over time with continuous treatment.
The authors of the analysis therefore suggested continuing treatment in patients who achieved partial response as long as possible to achieve best outcome.
They added that treatment of multiple myeloma should not only focus on achieving an initial response, but on achieving best outcome by treating patients beyond initial response.
Recent studies have shown that more relapsed and refractory patients achieve a complete or very good partial response with the Revlimid (lenalidomide)-dexamethasone (Decadron) combination treatment However, it is not clear if the quality of response is associated with better prognosis.
Read Michelle’s excellent article by going to: Revlimid-Dexamethasone Combination Yields Better Prognosis Any study which shows higher survival rates works for me! Nice to see some validation for those of us who believe multiple myeloma patients will live longer as novel therapies improve.
Feel good and keep smiling! Pat